Alison Reid
Papers
1
Total Citations
2
H-Index
1
About
Alison Reid is a urologic oncologist whose research focuses on optimizing treatment strategies for testicular cancer, particularly seminoma, through minimally invasive surgical techniques and chemotherapy de-escalation. Her most-cited work investigates the combination of minimally invasive retroperitoneal lymph node dissection (MI-RPLND) with single-dose carboplatin for clinical stage 2 seminoma—a paradigm-shifting approach aimed at reducing the toxicity of standard multi-cycle chemotherapy regimens like BEP or EP. This study, with 2 citations, provides early evidence that surgery plus a single chemotherapy dose may achieve comparable oncologic control while sparing patients from the cumulative side effects of traditional protocols. Reid’s contributions are especially notable for challenging the long-standing reliance on multi-agent chemotherapy in stage 2 disease, offering a potential path toward personalized, less morbid care. Her work sits at the intersection of surgical innovation and chemotherapeutic stewardship, making her a key voice in testicular cancer management. For trainees and researchers, Reid’s research exemplifies how targeted, multidisciplinary approaches can reshape treatment standards in genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1